# Tubulis (Gilead)

Source: https://onco.cc/companies/tubulis/  
OnCo record `tubulis` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead bought it in May 2026 for $3.15B upfront and up to $1.85B in milestones.

## Summary

Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead completed its acquisition on 21 May 2026, paying $3.15B upfront with up to $1.85B in contingent milestones; the acquisition also brought TUB-030, a 5T4-targeted ADC, and the team stays in Munich. Proprietary Tubutecan and P5 conjugation chemistries.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Munich
- Type: biotech
- Website: https://tubulis.com

## Notes

- Freshened 29 October 2026: the Gilead acquisition, announced earlier with a second-quarter 2026 close expected, was confirmed complete in Gilead's release of 21 May 2026. The Series C figure was not re-checked in this pass.

## Sources

- Gilead acquisition: https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis
- Gilead completes acquisition (May 2026): https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)
- trials: [FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC](https://onco.cc/trials/nct06303505/), [First in Human Study of TUB-030 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06657222/), [Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer](https://onco.cc/trials/nct07736937/), [Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct07806773/)

---
JSON: https://onco.cc/api/v1/entities/tubulis.json